Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. The result is extensive scarring in your bone marrow, leading to severe anemia, weakness, fatigue, and often, an enlarged spleen and liver. Myelofibrosis is an uncommon type of chronic leukemia — a cancer that affects the blood-forming tissues in the body. Myelofibrosis belongs to a group of diseases called myeloproliferative disorders.
An observational, multicenter and retrospective study on 3 hematology centers in Brazil was conducted. From a survey, some data were extracted from 103 medical records. The questionnaire included: demographic data, exposure to drugs, family history, manly reason for the first medical visit, symptoms, time to diagnosis confirmation, specialists evolved, tests acceded, laboratory finding, treatment.The median age was 69 years (29-99) and the highest prevalence was male (58%).
In the past, the treatment of myelofibrosis has depended on the symptoms and degree of the low blood counts. A long-term remission is possible for some patients with bone marrow transplantation. Such treatment should be considered for younger patients and some others. Other treatment may involve:Blood transfusions and medicines to correct anemia, Radiation and chemotherapy, Medicines to target a genetic mutation, Splenectomy if swelling causes symptoms, or to help with anemia.